NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Event: Q3 Investor Summit
Date: August 20th, 2024
Presentation Time: 2:00 pm ET
Location: https://www.webcaster4.com/Webcast/Page/3062/51117
The theme is 50 micro-cap companies with a catalyst and/or strong performance in the current market.
Take a deep dive with the best Investors in MicroCap
Live Q & A
Complimentary to Qualified Investors. Please REGISTER HERE.
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.
Contact:
Fred Rockwell
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Summit GroupSOURCE: Lixte Biotechnology Holdings, Inc.
| Last Trade: | US$4.88 |
| Daily Change: | 0.40 8.82 |
| Daily Volume: | 197,232 |
| Market Cap: | US$14.770M |
July 02, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
